Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

validation of a novel frailty risk score (UK-MRA Myeloma Risk Profile - MRP), usefulness of Karnofsky Performance Status (PS), and association of molecular subgroups with response, PFS and OS.

dexamethasone
lenalidomide
  • 0 views
  • 23 Jun, 2021
  • 109 locations
WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)

years, Karnofsky Performance Status (KPS) 70, life expectancy > 3 months, histological confirmation of primary tumor, with controlled or controllable extracranial disease, baseline Montreal

  • 0 views
  • 25 May, 2021
  • 4 locations
A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (ImproveCodel)

Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion. The prognosis of these molecularly defined tumors is to be determined in new series since survival data from older histology-based …

tumor progression
IDH2
lomustine
temozolomide
probe
  • 0 views
  • 06 May, 2022
  • 10 locations
Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases

This trial is a pilot, Phase 2, sequential two-cohort study designed to test two de-escalated whole brain radiation therapy (WBRT) dose levels and assess their ability to maintain acceptable in-brain distant control. The WBRT dose would decrease as the study moves forward, both in terms of absolute value and equivalent …

metastasis
whole-brain radiotherapy
solid tumor
  • 20 views
  • 10 Mar, 2022
  • 3 locations
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma

Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast (MN-166) and TMZ combination treatment for 1 cycle (28 days); determine dosage in dose-finding study. Part 2 will evaluate efficacy of fixed-dose MN-166 (ibudilast) and TMZ combination …

cancer
recurrent glioblastoma
gliadel wafer
gliadel
measurable disease
  • 13 views
  • 18 Sep, 2022
  • 1 location
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

platelet count
thromboplastin
liver metastasis
ct scan
metastasis
  • 20 views
  • 30 Jun, 2022
  • 3 locations
Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells

The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated …

prothrombin
meld score
encephalopathy
hepatitis
liver disease
  • 0 views
  • 13 Jul, 2022
  • 1 location
A Study of Front Line Ibrutinib for Newly Diagnosed Chronic Graft-Versus-Host Disease

Background Chronic Graft Versus Host Disease (cGVHD) can occur after a person has had a stem cell or bone marrow transplant. In cGVHD, the donor cells attack the recipient s body. Researchers want to see if a drug called ibruntinib can block one of the proteins that lead to the …

immunosuppressive agents
bone marrow transplant
urine test
beclomethasone
budesonide
  • 0 views
  • 20 Sep, 2022
  • 2 locations
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Background The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain. Researchers want to give the new drug LB100 to people before brain …

recurrent glioblastoma
astrocytoma
brain tumor
platelet count
gliosarcoma
  • 22 views
  • 19 Sep, 2022
  • 1 location
Role of Repeat Resection in Recurrent Glioblastoma

Patients with recurrent Glioblastoma (GBM) are commonly presented to surgeons, along with the question of whether or not to re-resect the recurrence. There is no Level 1 evidence to support a role for repeat surgery in this context, but a multitude of observational research suggests that repeat surgery may improve …

  • 0 views
  • 21 Apr, 2022
  • 1 location